MYND Life Sciences announces Depression Biomarker Diagnostic Program Post published:June 1, 2021 Post category:Press Release
Psychedelics and Cannabis ETF Launches on NYSE Arca in First for the U.S. Post published:June 1, 2021 Post category:News
Horizons ETFs Announces Methodology Update for the North American Psychedelics Index Post published:May 31, 2021 Post category:Press Release
Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials Post published:May 31, 2021 Post category:Press Release
Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed Insider Selling Post published:May 30, 2021 Post category:Psychedelic Bulletin
MYND Life Sciences Inc. Establishes Scientific Advisory Board Post published:May 28, 2021 Post category:Press Release
Renowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory Board Post published:May 27, 2021 Post category:Press Release
PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations Post published:May 27, 2021 Post category:Press Release
MindMed announces shareholder Meeting Results Post published:May 27, 2021 Post category:Press Release
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke Post published:May 27, 2021 Post category:Press Release